Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-PLGA
- Development stage
- Unknown
- Lead developer
- Sophia Al-Adwan
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Implantation
01
Overview
MSC-PLGA is an investigational autologous cell therapy developed by Sophia Al-Adwan at the University of Jordan's Cell Therapy Center for the treatment of aneurysmal bone cysts (ABCs). The therapy consists of mesenchymal stem cells (MSCs) harvested from the patient's own bone marrow, which are expanded in osteogenic media supplemented with platelet lysate and then seeded onto a biodegradable poly lactic-co-glycolic acid (PLGA) scaffold. This tissue-engineered construct is implanted into the cyst cavity to facilitate bone healing and regeneration, particularly in patients who have failed standard treatments like allografts. The approach is currently being evaluated in a Phase 1/2 clinical trial (NCT03066245).
- Other names
- Autologous Bone Tissue Constructed On Biodegradable Polymer
Beyond the preview
Go deeper on MSC-PLGA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-PLGA.